Skip to main content
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Cholangiocarcinoma
Efficacy and Safety of Tinengotinib in Patients With Advanced Refractory/Relapsed CCA Who Previously Received an FGFR Inhibitor
Read More
Cholangiocarcinoma
KLF5 Inhibition Reduces Tumor Growth and Sensitizes to Chemotherapy-Induced Cell Death in Experimental Models of CCA
Read More
Cholangiocarcinoma
Phase 2 Trial of SHR-1316 Plus IBI310 in Patients With Advanced iCCA After Inadequate Response to First-Line Therapy
Read More
Cholangiocarcinoma
Examination of Patients With CCA Treated With Novel Targeted Therapies After Extended Molecular Profiling on Liquid Biopsies
Read More
Cholangiocarcinoma
Phase 2 Component of the BEER-BTC Study: Comparing Bevacizumab Plus Erlotinib Maintenance Versus Observation in Patients With Advanced BTC
Read More
Cholangiocarcinoma
The DEBATE Trial: Neoadjuvant Durvalumab Plus GemCis Versus GemCis Alone for Patients With Localized BTC
Read More
Cholangiocarcinoma
The Phase 2 ADJUBIL Study of Durvalumab Plus Tremelimumab With or Without Capecitabine in BTC
Read More
Cholangiocarcinoma
Tucatinib and Trastuzumab in Patients With Previously Treated HER2-Positive Metastatic BTC: The SGNTUC-019 Study
Read More
Cholangiocarcinoma
Phase 2 BilT-02 Trial: Rucaparib and Nivolumab as Maintenance Therapy Following Chemotherapy in Patients With Advanced BTC
Read More
Cholangiocarcinoma
Results From the Phase 2b HERIZON-BTC-01 Study of Zanidatamab in Previously Treated HER2-Amplified BTC
Read More
21
22
23
24
25
26
27
Page 24 of 196
Results 231 - 240 of 1953
